Pregnancy Category: C
Treatment of various types of depression.Anxiety, insomnia, neuropathic and chronic pain syndromes.
Potentiates the effects of serotonin and norepinephrine in the CNS.
Has significant anticholinergic properties.
Also has antianxiety effect related to sedative properties.
Antidepressant and antianxiety action.
Absorption: Well absorbed following oral administration.
Distribution: Widely distributed; enters breast milk.
Protein Binding: 92% bound to plasma proteins.
Metabolism and Excretion: Extensively metabolized by the liver.
Half-life: 8 hr.
Time/action profile (antidepressant effect)
|PO||within 1–2 wk||2–6 wk||days–wks|
Contraindicated in: Angle-closure glaucoma; Recent MI; Prolongation of QTc interval; Cardiac arrhythmia; Heart failure.
Use Cautiously in: Pre-existing cardiovascular disease; Prostatic hyperplasia (increased susceptibility to urinary retention); History of seizures (threshold may be lowered); May ↑ risk of suicide attempt/ideation especially during dose early treatment or dose adjustment; Obstetric: Use only if clearly needed and maternal benefits outweigh risk to fetus; Lactation: May result in sedation in infant; discontinue drug or bottle feed; Pediatric: Suicide risk, especially at initiation of therapy, may be greater in children and adolescents; Geriatric: May be more susceptible to adverse effects; dosage reduction required.
Adverse Reactions/Side Effects
Central nervous system
- neuroleptic malignant syndrome (life-threatening)
- fatigue (most frequent)
- sedation (most frequent)
- extrapyramidal reactions
- tardive dyskinesia
Ear, Eye, Nose, Throat
- blurred vision (most frequent)
- dry eyes (most frequent)
- dry mouth (most frequent)
- arrhythmias (life-threatening)
- hypotension (most frequent)
- ECG changes
- constipation (most frequent)
- increased appetite
- weight gain
- paralytic ileus
- testicular swelling
- urinary retention
- sexual dysfunction
- blood dyscrasias
Drug-Drug interactionAmoxapine is metabolized in the liver by the cytochrome P450 2D6 enzyme, and its action may be affected by drugs that compete for metabolism by this enzyme, including other antidepressants, phenothiazines, carbamazepine, and class 1C antiarrhythmics including propafenone, and flecainide ; when these drugs are used concurrently with amoxapine, dosage reduction of one or the other or both may be necessary. Concurrent use of other drugs that inhibit the activity of the enzyme, includingcimetidine, quinidine, amiodarone, and ritonavir may result in ↑ effects of amoxapine.May cause hypotension, tachycardia, and potentially fatal reactions when used with MAO inhibitors (avoid concurrent use—discontinue 2 wk before starting amoxapine).Concurrent use with SSRI antidepressants may result in ↑ toxicity and should be avoided (fluoxetine should be stopped 5 wk before starting amoxapine).Concurrent use with clonidine may result in hypertensive crisis and should be avoided.Concurrent use with levodopa may result in delayed/decreased absorption of levodopa or hypertension.Blood levels and effects may be ↓ by rifamycins (rifapentine, rifampin, rifabutin ). Cimetidine, fluoxetine, phenothiazines, or oral contraceptives ↑ levels and may cause toxicity.Increased risk of extrapyramidal reactions with other drugs causing extrapyramidal reactions (phenothiazines ).
Oral (Adults) 50 mg 2–3 times daily, increase to 100 mg 2–3 times daily by end of 1 week (not to exceed 300 mg daily in outpatients, 600 mg daily in divided doses in hospitalized patients). Once optimal dose is achieved, may be given as a single bedtime dose; no single dose to exceed 300 mg.
Oral (Geriatric Patients) 25 mg 2–3 times daily, may be increased to 50 mg 2–3 times daily (not >300 mg/day).
Availability (generic available)
Tablets: 25 mg, 50 mg, 100 mg, 150 mg
- Monitor mental status (orientation, mood, behavior) frequently. Assess for suicidal tendencies, especially during early therapy. Restrict amount of drug available to patient.
- Monitor BP and pulse before and during initial therapy. Notify physician or other health care professional of decreases in BP (10–20 mmHg) or sudden increase in pulse rate. Patients taking high doses or with a history of cardiovascular disease should have ECG monitored before and periodically during therapy.
- Observe for onset of extrapyramidal side effects (akathisia—restlessness; dystonia—muscle spasms and twisting motions; pseudoparkinsonism—mask facies, rigidity, tremors, drooling, shuffling gait, dysphagia, pill-rolling motions of hands). Dose reduction or discontinuation may be necessary. Trihexyphenidyl or diphenhydramine may be used to control these symptoms.
- Monitor for tardive dyskinesia (lip smacking or puckering, puffing of cheeks, rhythmic chewing or worm-like movement of tongue and mouth, uncontrolled movements of extremities). Notify health care professional immediately if these symptoms occur; they may be irreversible.
- Monitor for development of neuroleptic malignant syndrome(fever, respiratory distress, tachycardia, convulsions, diaphoresis, hypertension or hypotension, pallor, tiredness, severe muscle stiffness, loss of bladder control). Notify health care professional immediately if these symptoms occur.
- Assess for sexual dysfunction.
- Lab Test Considerations: May cause ↑ serum prolactin levels.
- Monitor CBC and differential during chronic therapy. May rarely cause bone marrow suppression.
- In chronic therapy, periodically monitor hepatic and renal function. Serum glucose may be ↑ or ↓.
Potential Nursing DiagnosesIneffective coping (Indications)
Chronic pain (Indications)
Risk for injury (Side Effects)
- Dose increases should be made at bedtime because of sedation. Dosage titration is a slow process; may take weeks to months. May give entire dose (if <300 mg) at bedtime, when dose is stabilized.
- Taper amoxapine to avoid withdrawal effects.
- Oral: Administer medication with or immediately after a meal to minimize gastric irritation.
- Instruct patient to take medication as directed. Abrupt discontinuation may cause nausea, headache, and malaise.
- Inform patient of the possibility of extrapyramidal symptoms and tardive dyskinesia. Instruct patient to report these symptoms immediately.
- May cause drowsiness and blurred vision. Caution patient to avoid driving and other activities requiring alertness until response to drug is known.
- Orthostatic hypotension, sedation, and confusion are common during early therapy, especially in geriatric patients. Protect patient from falls and advise patient to make position changes slowly.
- Refer patient to nutritional or weight management program as appropriate.
- Advise patient to avoid alcohol or other CNS depressant drugs during and for 3–7 days after therapy.
- Instruct patient to notify health care professional if dry mouth or constipation persists or if urinary retention, uncontrolled movements, or rigidity occur. Sugarless candy or gum may diminish dry mouth, and an increase in fluid intake or bulk may prevent constipation. If these symptoms persist, dosage reduction or discontinuation may be necessary. Consult health care professional if dry mouth persists for more than 2 wk.
- Advise patient to inform health care professional if breast enlargement or sexual dysfunction occurs.
- Caution patient to use sunscreen and protective clothing to prevent photosensitivity reactions.
- Inform patient to monitor dietary intake. Increased appetite may lead to undesired weight gain.
- Advise patient to notify health care professional of medication regimen before treatment or surgery.
- Therapy for depression is usually prolonged. Emphasize the importance of follow-up exams to monitor effectiveness and side effects and to improve coping skills.
- Treatment is not a cure since symptoms can recur after discontinuation of medication.
- Refer to local support group.
- Pediatric: Caution parents/guardians of teenagers or children taking this medication about possible increase in suicide risk. Teach parents how to assess for suicidal thoughts and to report concerns immediately.
- Obstetric / Lactation: Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.
- Increased sense of well-being.
- Renewed interest in surroundings.
- Increased appetite.
- Improved energy level.
- Improved sleep.
- Decreased anxiety. Initial response may be noted in 4–7 days in some patients. Most patients respond within 2 wk.
a trademark for a tricyclic antidepressant (amoxapine).
amoxapineA tricyclic antidepressant of the dibenzoxazepine class.
Tardive dyskinesia, sedation, postural hypotension, cholinergic effects (e.g., dry mouth, blurred vision, constipation, urinary retention, weight gain), neuroleptic malignant syndrome, cardiovascular effects (EKG, slow AV conduction); withdrawal symptoms accompany abrupt withdrawal.
> 500 ng/mL.
30 hours as metabolite (8-hydroxyamoxipine).